RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 123 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $761,000 | -75.4% | 30,567 | -79.8% | 0.00% | -100.0% |
| Q2 2021 | $3,090,000 | +5730.2% | 151,446 | +6046.3% | 0.00% | – |
| Q1 2021 | $53,000 | -75.0% | 2,464 | -61.6% | 0.00% | – |
| Q4 2020 | $212,000 | +430.0% | 6,418 | +263.6% | 0.00% | – |
| Q3 2020 | $40,000 | -32.2% | 1,765 | -34.4% | 0.00% | – |
| Q2 2020 | $59,000 | -30.6% | 2,689 | -27.3% | 0.00% | – |
| Q4 2019 | $85,000 | +93.2% | 3,697 | +83.5% | 0.00% | – |
| Q3 2019 | $44,000 | +2.3% | 2,015 | +3.7% | 0.00% | – |
| Q2 2019 | $43,000 | – | 1,943 | +194200.0% | 0.00% | – |
| Q1 2019 | $0 | -100.0% | 1 | -99.5% | 0.00% | – |
| Q4 2018 | $6,000 | +100.0% | 216 | +105.7% | 0.00% | – |
| Q3 2018 | $3,000 | 0.0% | 105 | +20.7% | 0.00% | – |
| Q2 2018 | $3,000 | – | 87 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |